Moreover, CAR γδT may also be helpful in solving the antigen-loss problem as Rozenbaum et al. found that unlike general CD19 CAR-T cells, CD19 CAR γδT can also target CD19-negative leukemia cells to achieve complete tumor control, especially after zoledronate priming [47]. This evidence concerns the gene CD19 and neoplasm.